In its interim order, a vacation bench of justices G S Sistani and P S Teji said the National Pharmaceutical Pricing Authority's (NPPA) decision should be kept in abeyance till it decides the company's plea to review the ceiling fixed on the product.
Reckitt's application for reviewing the price control order is pending before the NPPA.
"The impugned order (of NPPA) should be kept in abeyance till the review application filed by petitioner (Reckitt) is decided. A week thereafter (of the decision), the petitioner can move the court if they have any grievances with regard to the findings," the court said disposing of the company's plea.
Appearing for the company, senior advocate P Chidambaram, had said that the order has been passed by respondent 2 (NPPA) without following the mandatory procedure under the Drug (Price Control) Order (DPCO) 2013 for arriving at the ceiling price.
He had also contended that NPPA's decision was illegal, arbitrary and ultra vires of the DPCO 2013.
He also said that Itch Guard, containing clotrimazole one per cent cream and manufactured by the petitioner, has a turnover of Rs 54.9 crore.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
